M

    Matinas BioPharma Holdings Inc (MTNB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.19
    -0.01 (-3.50%)

    Market Cap: $2.94M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    83%(29/35)
    Avg Surprise
    -14.49%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.21N/AN/ABeat+79.6%
    Mar 26
    		$-0.30N/AN/ABeat+9.1%
    Dec 25
    		$-0.30$0.00N/ABeat+62.9%
    Sep 25
    		$-0.40$0.00N/ABeat+52.9%
    Jun 25
    		$-1.03$0.00N/ABeat-5050.0%
    Mar 25
    		$-0.33N/A+57.69%Beat+78.0%
    Dec 24
    		$-0.81$-0.78-3.28%Miss-3928.0%
    Sep 24
    		$-0.85$-1.05+19.05%Beat+43.3%
    Jun 24
    		$-0.02N/A+98.00%Beat+98.7%
    Mar 24
    		$-1.50$-1.50+0.00%Beat+0.0%
    Dec 23
    		$-0.02$-0.03+33.33%Beat+0.0%
    Sep 23
    		$-1.50$-1.50+0.00%Beat+0.0%
    Jun 23
    		$-1.50$-1.50+0.00%Beat+0.0%
    Mar 23
    		$-1.50$-1.50+0.00%Beat+0.0%
    Dec 22
    		$-0.02$-0.03+33.33%Beat+33.3%
    Sep 22
    		$-1.50$-1.50+0.00%Beat+0.0%
    Jun 22
    		$-1.50$-1.50+0.00%Beat-50.0%
    Mar 22
    		$-1.50$-1.25-20.00%Miss+0.0%
    Dec 21
    		$-0.03$-0.03+0.00%Beat+0.0%
    Sep 21
    		$-1.50$-1.50+0.00%Beat+0.0%
    Jun 21
    		$-1.00$-1.75+42.86%Beat+33.3%
    Mar 21
    		$-1.50$-1.50+0.00%Beat-4900.0%
    Dec 20
    		$-0.03$-0.03+0.00%Beat+98.4%
    Sep 20
    		$-1.50$-1.67+10.18%Beat+0.0%
    Jun 20
    		$-1.50$-1.50+0.00%Beat+6.3%
    Mar 20
    		$-0.03$-0.03+0.00%Beat+98.5%
    Dec 19
    		$-1.83$-1.83+0.00%Beat-6000.0%
    Sep 19
    		$-1.50$-2.00+25.00%Beat+0.0%
    Jun 19
    		$-1.60$-2.00+20.00%Beat+20.0%
    Mar 19
    		$-2.00$-1.50-33.33%Miss+20.0%
    Dec 18
    		$-0.03$-0.03+0.00%Beat+25.0%
    Sep 18
    		$-1.50$-2.00+25.00%Beat+25.0%
    Jun 18
    		$-2.00$-2.00+0.00%Beat+0.0%
    Mar 18
    		$-2.50$-2.00-25.00%Miss+80.0%
    Dec 17
    		$-0.04$-0.04+0.00%Beat-33.3%
    Sep 17
    		$-2.00$-2.33+14.16%Beat+63.6%
    Jun 17
    		$-2.00$-2.33+14.16%Beat-
    Mar 17
    		$-12.50$-1.75-614.29%Miss-
    Dec 16
    		$-0.03N/A+62.50%Beat-
    Sep 16
    		$-5.50$-1.50-266.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.16EV/EBITDA-1.79x
    Price/FCF-0.19xFCF Yield-519.25%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-141.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.85xQuick Ratio0.85x
    Trading Statistics
    Beta1.75Avg Volume1.33M
    52-Week High$2.1452-Week Low$0.18

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.20
    SMA 20$0.23
    SMA 50$0.37
    SMA 200$0.60
    EMA 10$0.21
    EMA 20$0.24
    EMA 50$0.35
    EMA 200$0.61

    MACD

    Line: -0.05Signal: -0.06Hist: 0.01

    ADX

    ADX: 9.2+DI: 19.3-DI: 18.6

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down72.0
    PSAR$0.22

    Bollinger Bands

    Upper Band$0.30
    Lower Band$0.16
    %B Position6098%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    33.9

    Momentum Oscillators

    Stoch %K21.0
    Stoch %D20.3
    Williams %R-81.2
    ROC (10d)-13.1%
    Momentum-0.03
    CCI (20d)-84.3
    MFI (14d)59.2

    Volatility Measures

    ATR (14d)$0.04(18.8%)
    StdDev (20d)0.04
    Hist Vol127.9%(High)

    Volume Flow

    VWAP$0.19
    OBV221.5M
    AD Line-158.7M
    CMF (20d)0.103

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.3x(Low)
    VWMA (20d)$0.23

    Pivot Points

    R3$0.21
    R2$0.20
    R1$0.20
    Pivot Point$0.20
    S1$0.20
    S2$0.19
    S3$0.19

    Advanced Oscillators

    TSI-32.57
    Ultimate Osc48.7
    KST-398.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$-1,096,000$0
    Cost of Revenue$0$0$-85,000$0$0$0N/A$0$0$0$3.67M$0
    Gross Profit$0$0$85,000$0$0$0N/A$0$0$0$-3,665,000$0
    Operating Expenses$1.55M$1.94M$1.56M$1.58M$1.84M$1.95M$8.47M$4.38M$5.84M$5.90M$5.89M$6.13M
    R&D$0$0$0$0$0$85,000$2.38M$2.24M$3.37M$3.45M$3.67M$3.29M
    SG&A$1.55M$1.94M$1.60M$1.58M$1.84M$1.86M$1.66M$2.14M$2.47M$2.46M$2.22M$2.84M
    Operating Income$-1,555,000$-1,936,000$-1,600,000$-1,577,000$-1,837,000$-1,946,000$-8,471,000$-4,381,000$-5,839,000$-5,902,000$-5,887,000$-6,134,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$316,000$0$3.41M$0$0$0$0$0$0$0
    Income Before Tax$-1,326,000$-1,921,000$-1,916,000$-1,532,000$-5,245,000$-1,656,000$-8,209,000$-4,381,000$-5,839,000$-5,902,000$-5,314,000$-6,055,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,326,000$-1,921,000$-1,912,000$-1,532,000$-5,245,000$-1,656,000$-8,433,000$-4,275,000$-5,719,000$-5,824,000$-5,314,000$-6,055,000
    EBITDA$-1,322,000$-1,847,000$-1,526,000$-1,533,000$-5,123,000$-1,528,000$-7,513,000$-4,287,000$-5,932,000$-5,644,000$-5,541,000$-5,800,000
    EBIT$-1,326,000$-1,921,000$-1,953,000$-1,532,000$-5,245,000$-1,656,000$-8,209,000$-4,381,000$-5,839,000$-5,902,000$-5,798,000$-6,055,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MTNB

    News

    Hydrogen startup GH Power lines up deal with Matinas BioPharma (NYSE: MTNB)

    Matinas BioPharma (MTNB) is pursuing a business combination with Canadian clean energy company GH Power, expected to close in Q4 2026. GH Power's technology converts aluminum and water into fuel-cell-grade hydrogen, high-purity aluminum oxide, and thermal energy. The deal is contingent on several conditions, including GH Power securing at least $15.0 million in financing and shareholder approvals.

    Stock Titan•8/25/26•
    Somewhat-Bullish

    Matinas BioPharma (MTNB) holder Adam Stern details 9.99% stake and new warrants

    Adam Stern has updated his beneficial ownership in Matinas BioPharma (MTNB) to 2,972,524 shares, representing a 9.99% stake, and may control 13.1% of voting power due to preferred stock. The report details recent warrant exercises by Stern-related entities at $0.35 per share, which also resulted in the issuance of new unregistered warrants for an equal number of shares. These new warrants are exercisable for five years upon obtaining stockholder approval for the underlying shares and are subject to beneficial ownership limitations.

    Stock Titan•8/13/26•
    Neutral

    Enterprise value to revenue forward of Matinas BioPharma Holdings, Inc. – FWB:6LJ0

    This article provides the enterprise value to revenue forward for Matinas BioPharma Holdings, Inc. (FWB:6LJ0). It indicates that the market was closed at the time of the data capture and provides general navigation and copyright information for TradingView and its data providers.

    TradingView•8/8/26•
    Neutral

    Matinas BioPharma Holdings Inc (MTNB) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Matinas BioPharma Holdings Inc (MTNB), noting that no earnings forecast score is currently available. It details the stock's current price, market capitalization, and a peer comparison based on analyst ratings, with the most recent update on August 6, 2026. The report indicates that relevant financial forecasting data for EPS, Revenue, Net Profit, and EBIT have not yet been disclosed by the company.

    TradingKey•8/7/26•
    Neutral

    Matinas BioPharma (MTNB) to merge into new GH Power International parent

    Matinas BioPharma and GH Power Inc. have entered into a definitive Business Combination Agreement, under which they will merge into a newly formed Ontario corporation, GH Power International Inc. GH Power shareholders are expected to own approximately 91% of the combined entity, and Matinas stockholders about 9%. The combined company, focusing on GH Power’s modular reactor technology for clean hydrogen and critical minerals, aims to list on the NYSE American by the fourth quarter of 2026, contingent on various approvals and GH Power securing at least $15.0 million in financing.

    Stock Titan•8/4/26•
    Neutral

    Frequently Asked Questions About MTNB

    Does MTNB pay dividends?
    Matinas BioPharma Holdings Inc (MTNB) does not currently pay a regular dividend.
    What is MTNB's market cap?
    Matinas BioPharma Holdings Inc (MTNB) has a market capitalization of $2.94M with a current stock price of $0.19.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In